291 related articles for article (PubMed ID: 34965383)
1. Functional analysis of the 1p34.3 risk locus implicates GNL2 in high-grade serous ovarian cancer.
Nakamura K; Reid BM; Chen A; Chen Z; Goode EL; Permuth JB; Teer JK; Tyrer J; Yu X; Kanetsky PA; Pharoah PD; Gayther SA; Sellers TA; Lawrenson K; Karreth FA
Am J Hum Genet; 2022 Jan; 109(1):116-135. PubMed ID: 34965383
[TBL] [Abstract][Full Text] [Related]
2. Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer.
Lawrenson K; Li Q; Kar S; Seo JH; Tyrer J; Spindler TJ; Lee J; Chen Y; Karst A; Drapkin R; Aben KK; Anton-Culver H; Antonenkova N; ; Baker H; Bandera EV; Bean Y; Beckmann MW; Berchuck A; Bisogna M; Bjorge L; Bogdanova N; Brinton LA; Brooks-Wilson A; Bruinsma F; Butzow R; Campbell IG; Carty K; Chang-Claude J; Chenevix-Trench G; Chen A; Chen Z; Cook LS; Cramer DW; Cunningham JM; Cybulski C; Dansonka-Mieszkowska A; Dennis J; Dicks E; Doherty JA; Dörk T; du Bois A; Dürst M; Eccles D; Easton DT; Edwards RP; Eilber U; Ekici AB; Fasching PA; Fridley BL; Gao YT; Gentry-Maharaj A; Giles GG; Glasspool R; Goode EL; Goodman MT; Grownwald J; Harrington P; Harter P; Hasmad HN; Hein A; Heitz F; Hildebrandt MA; Hillemanns P; Hogdall E; Hogdall C; Hosono S; Iversen ES; Jakubowska A; James P; Jensen A; Ji BT; Karlan BY; Kruger Kjaer S; Kelemen LE; Kellar M; Kelley JL; Kiemeney LA; Krakstad C; Kupryjanczyk J; Lambrechts D; Lambrechts S; Le ND; Lee AW; Lele S; Leminen A; Lester J; Levine DA; Liang D; Lissowska J; Lu K; Lubinski J; Lundvall L; Massuger LF; Matsuo K; McGuire V; McLaughlin JR; Nevanlinna H; McNeish I; Menon U; Modugno F; Moysich KB; Narod SA; Nedergaard L; Ness RB; Azmi MA; Odunsi K; Olson SH; Orlow I; Orsulic S; Weber RP; Pearce CL; Pejovic T; Pelttari LM; Permuth-Wey J; Phelan CM; Pike MC; Poole EM; Ramus SJ; Risch HA; Rosen B; Rossing MA; Rothstein JH; Rudolph A; Runnebaum IB; Rzepecka IK; Salvesen HB; Schildkraut JM; Schwaab I; Sellers TA; Shu XO; Shvetsov YB; Siddiqui N; Sieh W; Song H; Southey MC; Sucheston L; Tangen IL; Teo SH; Terry KL; Thompson PJ; Timorek A; Tsai YY; Tworoger SS; van Altena AM; Van Nieuwenhuysen E; Vergote I; Vierkant RA; Wang-Gohrke S; Walsh C; Wentzensen N; Whittemore AS; Wicklund KG; Wilkens LR; Woo YL; Wu X; Wu AH; Yang H; Zheng W; Ziogas A; Monteiro A; Pharoah PD; Gayther SA; Freedman ML
Nat Commun; 2015 Sep; 6():8234. PubMed ID: 26391404
[TBL] [Abstract][Full Text] [Related]
3. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
[TBL] [Abstract][Full Text] [Related]
4. WNT Signaling Driven by R-spondin 1 and LGR6 in High-grade Serous Ovarian Cancer.
Lee S; Jun J; Kim WJ; Tamayo P; Howell SB
Anticancer Res; 2020 Nov; 40(11):6017-6028. PubMed ID: 33109540
[TBL] [Abstract][Full Text] [Related]
5. BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress.
Cesaratto L; Grisard E; Coan M; Zandonà L; De Mattia E; Poletto E; Cecchin E; Puglisi F; Canzonieri V; Mucignat MT; Zucchetto A; Stocco G; Colombatti A; Nicoloso MS; Spizzo R
Cell Death Dis; 2016 Sep; 7(9):e2374. PubMed ID: 27899818
[TBL] [Abstract][Full Text] [Related]
6. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube.
Karst AM; Levanon K; Drapkin R
Proc Natl Acad Sci U S A; 2011 May; 108(18):7547-52. PubMed ID: 21502498
[TBL] [Abstract][Full Text] [Related]
7. Ovarian Cancer Risk Variants Are Enriched in Histotype-Specific Enhancers and Disrupt Transcription Factor Binding Sites.
Jones MR; Peng PC; Coetzee SG; Tyrer J; Reyes ALP; Corona RI; Davis B; Chen S; Dezem F; Seo JH; Kar S; Dareng E; ; Berman BP; Freedman ML; Plummer JT; Lawrenson K; Pharoah P; Hazelett DJ; Gayther SA
Am J Hum Genet; 2020 Oct; 107(4):622-635. PubMed ID: 32946763
[TBL] [Abstract][Full Text] [Related]
8. Gene networks and expression quantitative trait loci associated with adjuvant chemotherapy response in high-grade serous ovarian cancer.
Choi J; Topouza DG; Tarnouskaya A; Nesdoly S; Koti M; Duan QL
BMC Cancer; 2020 May; 20(1):413. PubMed ID: 32404140
[TBL] [Abstract][Full Text] [Related]
9. Synchronous profiling of mRNA N6-methyladenosine modifications and mRNA expression in high-grade serous ovarian cancer: a pilot study.
Yang L; Liu J; Jin Y; Xing J; Zhang J; Chen X; Yu A
Sci Rep; 2024 May; 14(1):10427. PubMed ID: 38714753
[TBL] [Abstract][Full Text] [Related]
10. Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis.
Karagoz K; Mehta GA; Khella CA; Khanna P; Gatza ML
EBioMedicine; 2019 Dec; 50():191-202. PubMed ID: 31767542
[TBL] [Abstract][Full Text] [Related]
11. Reduced RBX1 expression induces chromosome instability and promotes cellular transformation in high-grade serous ovarian cancer precursor cells.
Bungsy M; Palmer MCL; Jeusset LM; Neudorf NM; Lichtensztejn Z; Nachtigal MW; McManus KJ
Cancer Lett; 2021 Mar; 500():194-207. PubMed ID: 33290867
[TBL] [Abstract][Full Text] [Related]
12. Tumor specific methylome in Chinese high-grade serous ovarian cancer characterized by gene expression profile and tumor genotype.
Song F; Li L; Zhang B; Zhao Y; Zheng H; Yang M; Li X; Tian J; Huang C; Liu L; Wang Q; Zhang W; Chen K
Gynecol Oncol; 2020 Jul; 158(1):178-187. PubMed ID: 32362568
[TBL] [Abstract][Full Text] [Related]
13. Global miRNA/proteomic analyses identify miRNAs at 14q32 and 3p21, which contribute to features of chronic iron-exposed fallopian tube epithelial cells.
Chhabra R; Rockfield S; Guergues J; Nadeau OW; Hill R; Stevens SM; Nanjundan M
Sci Rep; 2021 Mar; 11(1):6270. PubMed ID: 33737539
[TBL] [Abstract][Full Text] [Related]
14. Establishment and Characterization of the Novel High-Grade Serous Ovarian Cancer Cell Line OVPA8.
Tudrej P; Olbryt M; Zembala-Nożyńska E; Kujawa KA; Cortez AJ; Fiszer-Kierzkowska A; Pigłowski W; Nikiel B; Głowala-Kosińska M; Bartkowska-Chrobok A; Smagur A; Fidyk W; Lisowska KM
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018258
[TBL] [Abstract][Full Text] [Related]
15. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
16. Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci.
Coetzee SG; Shen HC; Hazelett DJ; Lawrenson K; Kuchenbaecker K; Tyrer J; Rhie SK; Levanon K; Karst A; Drapkin R; Ramus SJ; ; Couch FJ; Offit K; Chenevix-Trench G; Monteiro AN; Antoniou A; Freedman M; Coetzee GA; Pharoah PD; Noushmehr H; Gayther SA;
Hum Mol Genet; 2015 Jul; 24(13):3595-607. PubMed ID: 25804953
[TBL] [Abstract][Full Text] [Related]
17. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
[TBL] [Abstract][Full Text] [Related]
18. Deubiquitinase UCHL1 Maintains Protein Homeostasis through the PSMA7-APEH-Proteasome Axis in High-grade Serous Ovarian Carcinoma.
Tangri A; Lighty K; Loganathan J; Mesmar F; Podicheti R; Zhang C; Iwanicki M; Drapkin R; Nakshatri H; Mitra S
Mol Cancer Res; 2021 Jul; 19(7):1168-1181. PubMed ID: 33753553
[TBL] [Abstract][Full Text] [Related]
19. Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes.
Fridley BL; Jenkins GD; Tsai YY; Song H; Bolton KL; Fenstermacher D; Tyrer J; Ramus SJ; Cunningham JM; Vierkant RA; Chen Z; Chen YA; Iversen E; Menon U; Gentry-Maharaj A; Schildkraut J; Sutphen R; Gayther SA; Hartmann LC; Pharoah PD; Sellers TA; Goode EL
Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):529-36. PubMed ID: 22302016
[TBL] [Abstract][Full Text] [Related]
20. Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci.
Kar SP; Adler E; Tyrer J; Hazelett D; Anton-Culver H; Bandera EV; Beckmann MW; Berchuck A; Bogdanova N; Brinton L; Butzow R; Campbell I; Carty K; Chang-Claude J; Cook LS; Cramer DW; Cunningham JM; Dansonka-Mieszkowska A; Doherty JA; Dörk T; Dürst M; Eccles D; Fasching PA; Flanagan J; Gentry-Maharaj A; Glasspool R; Goode EL; Goodman MT; Gronwald J; Heitz F; Hildebrandt MA; Høgdall E; Høgdall CK; Huntsman DG; Jensen A; Karlan BY; Kelemen LE; Kiemeney LA; Kjaer SK; Kupryjanczyk J; Lambrechts D; Levine DA; Li Q; Lissowska J; Lu KH; Lubiński J; Massuger LF; McGuire V; McNeish I; Menon U; Modugno F; Monteiro AN; Moysich KB; Ness RB; Nevanlinna H; Paul J; Pearce CL; Pejovic T; Permuth JB; Phelan C; Pike MC; Poole EM; Ramus SJ; Risch HA; Rossing MA; Salvesen HB; Schildkraut JM; Sellers TA; Sherman M; Siddiqui N; Sieh W; Song H; Southey M; Terry KL; Tworoger SS; Walsh C; Wentzensen N; Whittemore AS; Wu AH; Yang H; Zheng W; Ziogas A; Freedman ML; Gayther SA; Pharoah PD; Lawrenson K
Br J Cancer; 2017 Feb; 116(4):524-535. PubMed ID: 28103614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
